Iron supplementation in premature infants using the zinc protoporphyrin to heme ratio: short-and long-term outcomes
INTRODUCTION
The majority of iron transfer from the placenta to the fetus occurs in the third trimester, increasing the likelihood that premature infants will have lower iron stores at birth. 1 Postnatally, frequent phlebotomy losses, rapid growth and delayed enteral iron supplementation exacerbate the risk for iron deficiency. 1, 2 Although blood transfusions may lessen the rate at which a neonate consumes iron stores, the emerging trend is toward less frequent blood transfusion in the neonatal intensive care unit. Thus, iron needs may vary widely for individual infants based on the maternal history, amount of blood drawn and transfused, as well as the amount of iron in their feedings. Consequently, iron supplementation is a critical treatment for premature infants.
Children with prolonged iron deficiency have irreversible developmental delays. [3] [4] [5] [6] [7] This is thought to be because of the fact that iron is essential for normal brain development as it is involved with many vital processes, including oligodendrocyte metabolism, myelination and monoamine metabolism. 3, 8 Animal studies of prenatal and postnatal iron deficiency have found decreased myelination of the brain and decreased brain mass. 9, 10 Infants of diabetic mothers, another group at risk for iron deficiency, have lower iron stores at birth due to an increased fetal iron demand for erythropoiesis and, as a result, have decreased brain iron stores on autopsy. 11 Premature infants with in utero iron deficiency have abnormal auditory neural maturation on auditory brainstem response. 12 The literature suggests that iron sufficiency must be maintained in the premature infant to protect iron stores in the brain and potentially the infant's long-term development.
Ideally, to diagnose iron deficiency, markers of iron status should be measured and an infant should be given the optimal amount of iron supplementation based on their needs. Currently, enteral iron supplements are started on premature infants at the discretion of the attending neonatologist, with a suggested dose range of 2 to 4 mg kg À 1 per day without the knowledge of iron status. 13, 14 There is no evidence indicating that this range is an adequate dose to prevent iron deficiency for all premature infants, as the recommendation is based in part on a small study using measures that have been invalidated in this population. 15 The standard practice of treating all premature infants with essentially the same dose of iron may lead to inadequate treatment and, in some cases, potential iron overload.
Classically, iron deficiency is diagnosed by an anemia, a low serum ferritin, an elevated total iron-binding capacity, an elevated soluble transferrin receptor and a low serum iron. In premature infants, however, the total iron-binding capacity, soluble transferrin receptor and serum iron have been shown to be unreliable measures due to developmentally specific changes in these values. 16, 17 It has long been recognized that anemia is a late finding in iron deficiency. Premature infants are typically anemic from a combination of anemia of prematurity and phlebotomy losses. Ferritin is a reliable marker of iron status when decreased, but may not reflect iron stores if it is elevated, as it is an acute phase reactant. The zinc protoporphyrin to heme ratio (ZnPP/H) has been proposed to be an indicator of pre-anemic iron deficiency in infants, children and adults. 18, 19 When iron is unavailable, zinc is incorporated into protoporphyrin IX of the red blood cell, causing the ZnPP/H to elevate. 20 In the premature infant, an elevated ZnPP/H is caused almost exclusively by iron-deficient erythropoiesis. Other reasons for an elevated ratio include lead intoxication and anemia of chronic disease, both not known to be common clinical conditions in the premature infant. 18, 19, 21 As the determination of the ZnPP/H is an inexpensive, easy-to-perform test that requires very little blood from the infant, it becomes a potentially clinically useful tool. Indeed, a pilot study in premature infants found that the ZnPP/H normalized with up to 12 mg kg À 1 per day of iron supplementation. There were no adverse effects of high doses of iron, including the markers of oxidative injury, serum and urine isoprostanes. 17 These pilot observations raised the possibility for optimization of iron status based on individual needs as reflected by the ZnPP/H.
Considering that the current screening tools to assess the iron needs of the growing premature infant are limited, this study sought to evaluate the changes in the ZnPP/H and ferritin; both are markers that have been promising in this population. We embarked on this prospective study with the following objectives. First, to determine the effect of incrementally higher doses of iron on the ZnPP/H and serum ferritin levels, and second, the 6-and 24-month developmental outcomes in premature infants at risk for iron deficiency. The hypothesis of this study is that infants receiving a higher dose of iron based on the ZnPP/H will normalize the ratio and ferritin levels relative to a control group receiving a standard iron dose. As a consequence of improved iron status, the infants would have improved neurodevelopmental outcome.
METHODS
This was a prospective, randomized, controlled blinded trial comparing a varying dose of iron supplementation given to a treatment group with a consistent standard dose of iron given to a control group. The total dose of iron used in both groups included the amount estimated in their feeding. None of the infants were receiving iron supplements at the time of enrollment. The control group received a constant iron dose of 2.2 mg kg À 1 per day. The treatment group received iron dosing based on previously determined ZnPP/H reference ranges for this population, using a sliding scale (Table 1) . 22 The dose range of 3 to 12 mg kg À 1 per day is the same range that was used in the above mentioned pilot study. 17 The ferrous sulfate dose for the control group was consistent with the range recommended by the American Academy of Pediatrics, and it is the amount of enteral iron an infant would receive on full feedings at a goal of 120 kcal kg À 1 per day of fortified preterm formula. 13, 14 Subjects were enrolled at the Crouse Hospital Neonatal Intensive Care Unit from May 2006 through October 2008. The Crouse Hospital Institutional Review Board approved this study. The parents gave informed consent before enrollment. Infants were eligible if they were born between 27 and 30 completed weeks of gestation, older than 1 week of age at study entry and were tolerating 100 ml kg À 1 per day of enteral feedings. Infants were ineligible if they were 35 weeks corrected gestational age or greater, had major, life-threatening anomalies, culture-proven sepsis within 48 h of study entry, perinatal asphyxia with Apgar score of o3 at 5 min or pHo7.1 on first arterial blood gas, bilateral grade IV intraventricular hemorrhage, were diagnosed with necrotizing enterocolitis, or were being treated with erythropoietin or ferrous sulfate.
Infants were enrolled and randomly assigned to control or treatment group by the Crouse Hospital Investigational Drug Pharmacy. All investigators and participants in the study were blinded to the treatment group. The maternal as well as the subject's medical records were reviewed for pertinent history. The ZnPP/H, hematocrit, reticulocyte count and serum ferritin were evaluated upon study entry and completion. The ZnPP/H was also evaluated weekly to allow for dosing adjustments. The Investigational Drug Pharmacy calculated the ferrous sulfate dose based on the amount of iron in the enteral feeding. The ferrous sulfate was started immediately after study entry and adjusted for weight gain weekly for both groups. The ferrous sulfate was given in divided doses twice daily before the feeding. All infants were treated with polyvisol while on ferrous sulfate, to ensure adequate vitamin E intake. If an infant was made NPO during the study, the iron was held until the feedings were resumed. The protocol did not address blood transfusions, which were ordered by the attending physician based on clinical assessment of the patient. Anthropometric measures were collected at study entry, on a weekly basis during the study period, and again at both follow-up visits when subjects were 6 and 24 months corrected gestational age. The study drug was continued through the 35th week corrected gestational age for all patients enrolled in this study. Infants were discharged home with iron supplements at the discretion of the attending physician. Infants returned to the Crouse Hospital High Risk Infant Follow-Up Clinic for examination with the Bayley Scales of Infant Development (Third Edition) at 6 and 24 months corrected gestational age. This was coordinated with their routine follow-up visit.
Laboratory tests
The ZnPP/H was tested at the Crouse Hospital Laboratory using the ProtoFluor Z hematofluorometer by Helena Laboratories (Beaumont, TX, USA) using a previously described method. 17 
Statistical analysis
The sample size was calculated based on results of the pilot study showing that 80 infants were required to sufficiently power a study to identify a significant treatment effect on the ZnPP/H. The desired treatment effect was normalization of the ZnPP/H based on the reference ranges. The data were analyzed using two-sample Student's t-tests, paired Student's t-tests and Fisher's exact test with post hoc testing as appropriate. It is reported as mean ± s.d. Results are considered statistically significant if the Po0.05.
RESULTS

General
Of the 118 eligible infants, 81 (69%) were enrolled with 41 in the treatment group and 40 in the control group (Figure 1 ). There were no significant differences in demographics between the two groups ( Table 2 ). The average ferrous sulfate dose for infants in the treatment group was significantly higher when compared with the control group (10.4 vs 2.2 mg kg À 1 per day; Po0.05). Infants tolerated the oral iron supplements and did not have any adverse Abbreviation: ZnPP/H, zinc protoporphyrin to heme ratio.
Iron supplementation in premature infants SM Miller effects, including gastrointestinal upset defined as vomiting or residuals, and constipation. Overall, 61% of infants in the study were fed with predominantly breast milk and there was no difference between the two groups.
Laboratory measures
The ZnPP/H at study entry for the treatment versus control infants (that is, 176 ± 56 vs 198 ± 72 mmol mol À 1 ) and at study completion (that is, 174 ± 58 vs 190 ± 72 mmol mol À 1 ), respectively, was not different between and within groups. The ZnPP/H was higher in infants fed mostly breast milk compared with those fed mostly formula at the end of the study, that is, 206 ± 73 vs 153 ± 59 mmol mol À 1 , Po0.05. At the end of the study, the serum ferritin level was decreased in the control group as compared with the initial levels, that is, 202 ± 109 vs 168 ± 141 ng ml À 1 , respectively (Po0.05), but remained stable in the treatment group, that is, 187 ± 131 vs 176 ± 118 ng ml À 1 (P ¼ 0.59). At study entry, the hematocrit was not significantly different between the treatment and control groups (28% vs 29%, respectively). Upon study completion, the hematocrit was significantly decreased within groups, that is, 28 to 25% in the treatment group and 29 to 24% in the control group (Po0.05), but there was no difference between groups. The reticulocyte count increased significantly in both groups by the end of the study, that is, 2.8 to 4.7% in the treatment group and 2.8 to 4% in the control group (Po0.05), but there was no difference between groups.
Blood transfusions Blood transfusions were comparable between groups, that is, 39% of treatment infants vs 43% of the control group (nonsignificant).
Of the infants who were transfused, 44% were transfused before the study entry, 47% were transfused both before and during the study period and 9% were transfused only during the study period. Infants who received a blood transfusion had a significantly decreased ZnPP/H compared with those who did not (154 ± 66 vs 206 ± 71 mmol mol À 1 , respectively; Po0.05). There was no difference in the ZnPP/H ratios between groups for infants who were transfused (treatment 143±65 mmol mol ). There was a significant increase in ferritin for infants who were transfused, compared with those who were not transfused (210±127 vs 144±123 ng ml À 1 , respectively; Po0.05). For infants who were not transfused, there was a significant increase in the reticulocyte count when comparing the beginning with the end of the study in both groups (treatment pre 3% and post 5.7% vs control pre 2.9% and post 4.4%; Po0.05). This was not seen for infants who received a transfusion.
Six-month follow-up Thirty-eight (93%) subjects in the treatment group and 33 (83%) in the control group returned for their 6-month follow-up. Measures of growth, including head circumference (43.3 ± 2 vs 43.7 ± 2 cm), length (64.6±3.3 vs 64.3±4.5 cm) and weight (7.44±1.4 vs 7.64 ± 1.6 kg) were not different between the treatment and control groups, respectively. There was no difference between the treatment and control group's Bayley Scales of Infant Development cognitive (100±11 vs 98±16), motor (89±15 vs 88±16) and language (93 ± 14 vs 88 ± 12) scores, respectively.
Twenty-four months follow-up For the 24-month follow-up, 28 treatment (68%) and 33 control (83%) subjects were evaluated. Measures of growth were not different between the treatment and the control group for head circumference (48.1±1.9 vs 48.6±2.4 cm), length (84.1±3.7 vs 83.4±6.8 cm) and weight (11.7±1.6 vs 12.1±1.8 kg). For the overall Bayley Scales of Infant Development scores, there were no differences between treatment and control groups in cognitive (96±11 vs 92±16), motor (100±11 vs 96±16) and language (101 ± 16 vs 95 ± 18) scores, respectively. In a post hoc analysis, to evaluate a specific difference in each area (that is, cognitive, motor and language), we identified a subgroup of infants with motor delays, a psychomotor development index o85 in 7% in the treatment group and 25% in the control group (odds ratio, 4.2; 95% confidence interval, 0.7 to 43; P ¼ 0.07).
DISCUSSION
The salient findings of this randomized study in growing premature infants treated with a varying dose of iron supplements Figure 1 . This chart outlines the number of eligible infants, those consented and not consented, and the outcome of the infants enrolled. Poor feeding means inability to obtain full feedings in the enrollment period. Two infants died in the control group after discharge from the neonatal intensive care unit. Iron supplementation in premature infants SM Miller include comparable ZnPP/H ratios at study completion and decreased serum ferritin levels in the control group at the end of the study, and infants who were transfused with blood had a significantly decreased ZnPP/H and higher serum ferritin level. There were no differences in hematocrit concentrations or reticulocyte values between groups at study completion. There were no overt side effects from using a higher dose of ferrous sulfate. ZnPP/H is a marker for iron-deficient erythropoiesis, and ferritin is a marker of iron stores. Total iron intake up to 12 mg kg À 1 per day was well tolerated and infants did not have any adverse effects, including feeding intolerance. Several other studies have also shown that oral iron supplements are well tolerated in infants and do not cause adverse gastrointestinal side effects. 17, 23, 24 Our previous study found no effect of iron dose on markers of oxidative injury. 17 With higher doses of iron supplements in the treatment group, it was anticipated that a decrease in the ZnPP/H ratio would be apparent by the end of the study period. However, no differences between the two groups was noted. Interestingly, infants who were predominantly breast fed had higher ZnPP/H ratios at study conclusion. It is unclear as to why this would be the case. To the contrary, one would expect better iron absorption with breast milk and, thus, a lower ZnPP/H ratio, even though the amount of iron in breast milk is lower. Administration of blood was associated with a decrease in the ZnPP/H ratio. Transfusion of packed red blood cells has been previously shown to decrease the ZnPP/H. This is thought to be due to a combination of adding adult red blood cells to the infant's blood (which has a lower ZnPP/H), as well as providing a source of iron. 25, 26 Though higher doses of iron were given, a possible reason for the lack of response of the ZnPP/H includes rapid postnatal growth of the infants. The erythropoietic demands of the infants may have been met and the iron may have gone to replenishing the stores. In addition, Cheng et al. 26 recently published a report, suggesting that the ZnPP/H normative values are higher postnatally than what was previously found. 22 Though the ZnPP/H was not helpful in determining adequacy of iron supplements, the findings of elevated serum ferritin levels at study conclusion in the treatment group are intriguing. First, as expected, the ferritin increased with blood transfusion. Second, the final ferritin was stable in the treatment group; however, the level in the control group had decreased at the end of the study. The lower values in the control infants were not in the range observed in infants with iron deficiency, likely because of the fact that the infants were receiving some iron, though 2.2 mg kg À 1 per day is at the low end of the suggested range. However, the trend in the control group is toward depletion of iron stores. As the average study time was only about 3 weeks, it is unclear whether the trend would be to lower ferritin levels over a longer period of time for these at risk infants.
The findings at 24 months show higher rates of motor delay in the control group in a post hoc analysis (Po0.10). It is tempting to speculate that this observation may reflect depleted iron stores at a time when there is rapid oligodendroglial differentiation. Importantly, this study was not powered to address this observation. The concern of depleted iron stores in the brain and long-term sequelae was first identified over 30 years ago by Dallman et al. 27 in a rat model of iron deficiency. Since that time, numerous animal studies have shown a correlation between decreased myelination of the brain in iron deficiency and adverse behavioral measures. 9, 10 Human studies on infants with iron deficiency show motor impairment as well as impaired mental development. [28] [29] [30] The risk of motor delay has never been correlated with depleting iron stores in premature infants in a randomized controlled trial. Although this study shows a trend, it is not large enough to show statistical significance. It is known that to support erythropoiesis, storage iron is preferentially shifted to the red blood cell. 11, 31 This depletion of storage iron, specifically in the brain, may contribute to the developmental delays in iron deficiency. The potential relationship between motor delays and lower doses of iron supplementation suggests a link between myelination and depletion of iron stores in infants at risk for iron deficiency. Amin et al. 12 recently published findings showing abnormal auditory brainstem-evoked response in premature infants with latent iron deficiency, defined as low ferritin at birth. The abnormal auditory brainstem-evoked response is further evidence to suggest that the effects of low iron stores may lead to early neurodevelopmental changes that can have long-lasting consequences in the premature infant. The infants in his study had low ferritin levels, whereas our study did not. However, the trend in our study is concerning and deserves further evaluation through a larger randomized clinical trial.
The major strength of this study is that it is a large prospective randomized trial comparing the two groups with follow-up at 24 months corrected age. This study does have a few limitations. The infants in this study were followed on the iron supplements for an average of 3 weeks, which may not be the enough time to adequately assess the change in ZnPP/H and ferritin. We did not collect information on infections as a potential complication of iron supplementation to compare the rate between the two groups. Another limitation was that we did not have 100% of our subjects follow-up, as is often the case with long-term follow-up studies. There may be a bias for impaired children to return to the scheduled follow-up visit over normal children, but this is unknown for our study. In addition, the finding of motor delays in a post hoc subgroup analysis is based on a limited number of patients for whom this study was not adequately powered. Finally, although we did not see any adverse effects, this was not a safety study and was not powered for adverse effects.
In summary, our findings suggest that the iron stores of premature infants are easily depleted, even with the standard practice of oral iron supplementation. It is concerning as this depletion may lead to neurodevelopmental delays. ZnPP/H is not a reliable indicator of iron status when used in short term (3 to 4 weeks). Ferritin may prove to be a better measure when assessing iron status in premature infants. Iron deficiency and depletion of iron stores in the brain is a serious health issue facing premature infants. There is an urgent need to focus on this nutrient deficiency in future studies, as the result may lead to dramatic changes in the outcomes of premature infants.
